Enliven Therapeutics, Inc (NASDAQ: ELVN) reported Q3 EPS of ($0.32), $0.18 better than the analyst estimate of ($0.50).

For earnings history and earnings-related data on Enliven Therapeutics, Inc (ELVN) click here.